EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD)



Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD)



Bioorganic & Medicinal Chemistry Letters 22(1): 138-143



Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease associated with irreversible progressive airflow limitation. Matrix metalloproteinase-12 (MMP-12) has been characterized to be one of the major proteolytic enzymes to induce airway remodeling, destruction of elastin and the aberrant remodeling of damaged alveoli in COPD and asthma. The goal of this project is to develop and identify an orally potent and selective small molecule inhibitor of MMP-12 for treatment of COPD and asthma. Syntheses and structure-activity relationship (SAR) studies of a series of dibenzofuran (DBF) sulfonamides as MMP-12 inhibitors are described. Potent inhibitors of MMP-12 with excellent selectivity against other MMPs were identified. Compound 26 (MMP118), which exhibits excellent oral efficacy in the MMP-12 induced ear-swelling inflammation and lung inflammation mouse models, had been successfully advanced into Development Track status.

(PDF emailed within 0-6 h: $19.90)

Accession: 052644934

Download citation: RISBibTeXText

PMID: 22153340

DOI: 10.1016/j.bmcl.2011.11.046



Related references

A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408). Journal of Medicinal Chemistry 52(7): 1799-1802, 2009

Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). Bioorganic and Medicinal Chemistry Letters 11(4): 571-574, 2001

Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic obstructive pulmonary disease (COPD). Current Medical Research and Opinion 21(4): 587-594, 2005

Chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary disease : Advances on the diagnosis and treatment.Diagnosis and disease state.Clinical manifestation and physical findings of COPD. Nihon Naika Gakkai Zasshi 84(5): 699-703, 1995

Chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary disease : Advances on the diagnosis and treatment.Diagnosis and disease state.Histopathology of a disease group presenting COPD. Nihon Naika Gakkai Zasshi 84(5): 730-734, 1995

Chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary disease : Advances on the diagnosis and treatment.Diagnosis and disease state.Disturbance of pulmonary circulation of COPD. Nihon Naika Gakkai Zasshi 84(5): 721-725, 1995

The discovery and optimization of potent non-peptidic matrix metalloprotease inhibitors. Abstracts of Papers American Chemical Society 214(1-2): MEDI 111, 1997

Chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary disease : Advances on the diagnosis and treatment.Treatment.Surgical treatment in COPD. Nihon Naika Gakkai Zasshi 84(5): 765-767, 1995

Chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary disease : Advances on the diagnosis and treatment.Diagnosis and disease state.Hypoxemia acidosis of COPD. Nihon Naika Gakkai Zasshi 84(5): 710-715, 1995

Chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary disease : Advances on the diagnosis and treatment.Diagnosis and disease state.Diagnostic criteria of COPD. Nihon Naika Gakkai Zasshi 84(5): 681-686, 1995

Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). Journal of Medicinal Chemistry 58(17): 6747-6752, 2015

Chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary disease : Advance on the diagnosis and treatment.Treatment.Acute aggravation and points of treatment. Nihon Naika Gakkai Zasshi 84(5): 756-760, 1995

Chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary disease : Advance on the diagnosis and treatment.Treatment.The significance of nutritional management. Nihon Naika Gakkai Zasshi 84(5): 750-755, 1995

Patients with chronic obstructive pulmonary disease (COPD)--similarities and differences of the study group participating in the project of National Center for Research and Development project "Chronic obstructive pulmonary disease (COPD)--systemic disease, the biggest threat of XXI century". Polski Merkuriusz Lekarski 39(234): 359-363, 2016

Chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary disease : Advance on the diagnosis and treatment.Diagnosis and disease state.Epidemiology and cause of COPD. Nihon Naika Gakkai Zasshi 84(5): 687-692, 1995